“we expect to transition from limited market to a full market release in the third quarter.”

In context

“demand is a result of evolving market dynamics, including expanding access to health care, aging populations, and a rising need to treat both acute and chronic conditions. These structural tailwinds combined with our broad portfolio expanding pipeline of biosimilars and strong brand equity position EPD to sustainably deliver high single digit sales growth. And I will wrap up with medical devices where sales grew 8.5% Growth of 8.5 percent in our cardiovascular device portfolio was led by low growth in electrophysiology and high single digit growth in rhythm management heart failure. In electrophysiology, the second quarter marked beginning of an acceleration in our growth trajectory. We launched our next generation Bolt PFA catheter, commonly referred to as Bolt 2.0, in the US in May, and we expect to transition from limited market to a full market release in the third quarter. Internationally, the expanding rollout of Bolt and Tactiflex Duo is gaining strong traction. Driving growth of more than 20% in Europe. Remain confident in our outlook for the second half of the year, including our expectations to begin outperforming the market and recapturing share. In Rhythm Management, sales grew 9.5% as we continue to expand the use of Avera across both the single and dual chamber segments of pacemaker market and to drive broader adoption of this innovative technology In heart failure, growth of 9% was led by double-digit growth in the US, driven by our market leading portfolio of heart assist devices that address both chronic and acute patient needs. In diabetes care, continuous glucose monitoring sales exceeded $2 billion, reflecting growth of 9.5% in the quarter. I”